Dupixent®

Random entry RSS

Posted in:
Legal

The Third Time is the Charm for Sanofi in its IPR Challenge of Immunex’s ʼ487 Patent
By Seth Cockrum February 27, 2019 Comments are off
On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron...

Read more

Tagged with: District Court, dupilumab, Dupixent®, Immunex, IPR, Legal, PTAB, Sanofi

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
Legal

Immunex Loses Battle Over Institution of Follow-on IPR Petitions
By Andrew Storaska and Jennifer P. Nock March 23, 2018 Comments are off
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. recently scored a victory in their ongoing dispute over a...

Read more

Tagged with: District Court, Dupixent®, Follow-on petitions, Genzyme, Immunex, IPR, PTAB, Regeneron, Sanofi

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
Legal

Sanofi, Genzyme, and Regeneron Voluntarily Dismiss Dupixent® (Dupilumab) Declaratory Judgment Suit in Massachusetts
By Seth Cockrum and C. Nichole Gifford May 8, 2017 Comments are off
The battle over the proper forum for patent infringement litigation regarding Dupixent® (Dupilumab) appears to have been resolved. Last...

Read more

Tagged with: Amgen, District Court, dupilumab, Dupixent®, Genzyme, Immunex, IPR, Legal, Litigation, PTAB, Regeneron, Sanofi, USPTO

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
Legal

Immunex Files Patent Infringement Suit Over Dupixent® (Dupilumab) and Seeks to Dismiss or Transfer Sanofi and Regeneron’s Prior DJ Complaint
By C. Nichole Gifford and Seth Cockrum April 12, 2017 Comments are off
As we previously reported, Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. filed a Declaratory Judgment...

Read more

Tagged with: Amgen, District Court, dupilumab, Dupixent®, Immunex, Legal, Litigation, Regeneron, Sanofi

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
News

Sanofi and Regeneron Follow Declaratory Judgment Complaint with an IPR Petition as FDA Approves Dupixent® (dupilumab)
By C. Nichole Gifford and Seth Cockrum March 30, 2017 Comments are off
We reported last week that Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. had filed suit in...

Read more

Tagged with: Amgen, dupilumab, Dupixent®, Immunex, IPR, Legal, PTAB, Regeneron, Sanofi, USPTO

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:
Legal

Sanofi and Regeneron Seek Declaratory Judgment that Dupixent® (Dupilumab) Does Not Infringe Amgen’s Patent
By C. Nichole Gifford and Seth Cockrum March 22, 2017 Comments are off
Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. (collectively “Plaintiffs”) filed a Complaint in the...

Read more

Tagged with: Amgen, District Court, dupilumab, Dupixent®, Immunex, Legal, Litigation, Regeneron, Sanofi

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus